ARGX
Healthcareargenx SE
$800.88
$-39.11 (-4.66%)
Jan 5, 2026
Price History (1Y)
Analysis
argenx SE is a biotechnology company operating in the healthcare sector. With a market capitalization of $49.88 billion and annual revenue of $3.68 billion, it is a significant player in its industry. The company employs 1599 individuals. The financials of argenx SE indicate substantial profitability, with gross margin at 54.8%, operating margin at 30.4%, and profit margin at 41.6%. Net income over the trailing twelve months amounts to $1.53 billion. Cash reserves stand at $3.93 billion, while debt is reported as $43.15 million. The company's debt-to-equity ratio is 0.71. Valuation metrics for argenx SE include a P/E ratio of 36.01 and forward P/E of 26.91. Revenue growth over the past year has been significant at 95.5%, while earnings growth was even higher at 272.7%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Visit website →Key Statistics
- Market Cap
- $49.88B
- P/E Ratio
- 36.01
- 52-Week High
- $934.62
- 52-Week Low
- $510.06
- Avg Volume
- 328.19K
- Beta
- -0.13
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- Netherlands
- Employees
- 1,599